ATI-2173

DRUG3 trials

Sponsors

Antios Therapeutics, Inc

Conditions

Drug Drug InteractionHepatitis B, ChronicHepatitis D

Phase 1

A Phase 1 Double-Blinded Study for Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ATI-2173 in Healthy Subjects and Subjects With Chronic Hepatitis B Virus Infection

CompletedNCT04248426

Antios Therapeutics, IncHepatitis B, Chronic

Start: 2020-02-05End: 2021-05-18Updated: 2021-08-19

A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects

CompletedNCT05137600

Antios Therapeutics, IncDrug Drug Interaction

Start: 2021-10-28End: 2022-01-23Updated: 2022-02-04

Phase 2

A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection

TerminatedNCT04847440

Antios Therapeutics, IncHepatitis B, Chronic, Hepatitis D

Start: 2021-03-30End: 2022-09-01Updated: 2022-11-18

Related Papers

A randomized phase 1b trial of the active site polymerase inhibitor nucleotide <scp>ATI</scp>‐2173 in patients with chronic hepatitis B virus infection

Journal of Viral Hepatitis2022-10-069 citations